NEW YORK (TheStreet) -- "I think this is becoming a non-speculative stock," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said of GW Pharmaceuticals (GWPH) on CNBC's "Cramer's Stop Trading" segment.
The company has released its preliminary data for Epidiolex, its cannabinoid treatment aimed at treatment-resistant epilepsy in children.
Cramer argued that the U.S. doesn't seem to understand the importance of medical marijuana, as it would be illegal for companies to create the non-laced marijuana treatment that GW Pharmaceuticals, a British-based company, has.
After 12 weeks, the drug showed at least a 50% reduction in seizures for 48% of the patients, with 15% of patients reportedly being seizure-free.
Cramer said he believes the Food and Drug Administration will approve this treatment, as it is proving helpful to these children.
He concluded that GW Pharmaceuticals is a "real company, doing real things."
-- Written by Bret Kenwell in Petoskey, Mich.